{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:32:09Z","timestamp":1790087529523,"version":"4.0.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Anales de Pediatr\u00eda (English Edition)"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.anpede.2025.503836","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T19:57:25Z","timestamp":1747339045000},"page":"503836","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Improvement of intestinal inflammation after treatment with CFTR modulators in cystic fibrosis patients"],"prefix":"10.1016","volume":"102","author":[{"given":"Ruth","family":"Garc\u00eda Romero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concepci\u00f3n","family":"L\u00f3pez C\u00e1rdenes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Crehu\u00e1 Gaudiza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"\u00c1lvarez Beltr\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Murray Hurtado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Tutau G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e9s","family":"Loverdos Eseverri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Encarni","family":"Torcuato Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila","family":"Garc\u00eda Volpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Salcedo Lobato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Medina Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Martin Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Moreno \u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Reyes Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gonz\u00e1lez Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saioa Vicente","family":"Santamar\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Tabares","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Ramon Gutierrez","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Sierra San","family":"Nicol\u00e1s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar Ortiz","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Pe\u00f1a","family":"Quintana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.anpede.2025.503836_bib0005","first-page":"91","article-title":"Fibrosis quistica y sus manifestaciones respiratorias","volume":"XXV","author":"L\u00f3pez Neyra","year":"2021","journal-title":"Pediatr Integral"},{"issue":"10290","key":"10.1016\/j.anpede.2025.503836_bib0010","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/S0140-6736(20)32542-3","article-title":"Cystic fibrosis","volume":"397","author":"Shteinberg","year":"2021","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.anpede.2025.503836_bib0015","article-title":"Newly discovered cutting-edge triple combination cystic fibrosis therapy: a systematic review","volume":"14","author":"Dawood","year":"2022","journal-title":"Cureus."},{"issue":"21","key":"10.1016\/j.anpede.2025.503836_bib0020","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1056\/NEJMoa1709847","article-title":"Tezacaftor-ivacaftor in residual-function heterozygotes with cystic fibrosis","volume":"377","author":"Rowe","year":"2017","journal-title":"N Engl J Med."},{"issue":"10212","key":"10.1016\/j.anpede.2025.503836_bib0025","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet."},{"key":"10.1016\/j.anpede.2025.503836_bib0030","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.27125","article-title":"Effectiveness and safety of elexacaftor\/tezacaftor\/ivacaftor treatment in children aged 6-11 years with cystic fibrosis in a real-world setting","author":"Dacc\u00f2","year":"2024","journal-title":"Pediatr Pulmonol."},{"issue":"19","key":"10.1016\/j.anpede.2025.503836_bib0035","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor- tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med."},{"key":"10.1016\/j.anpede.2025.503836_bib0040","article-title":"CFTR modulators: the changing face of cystic fibrosis in the era of precision medicine","volume":"10","author":"Lopes-Pacheco","year":"2019","journal-title":"Front Pharmacol."},{"issue":"4","key":"10.1016\/j.anpede.2025.503836_bib0045","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ccm.2022.06.009","article-title":"Update on clinical outcomes of highly effective modulator therapy","volume":"43","author":"Gifford","year":"2022","journal-title":"Clin Chest Med."},{"issue":"8","key":"10.1016\/j.anpede.2025.503836_bib0050","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1002\/ppul.26486","article-title":"Radiological and long-term clinical response to elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis with advanced lung disease","volume":"58","author":"Aalbers","year":"2023","journal-title":"Pediatr Pulmonol"},{"issue":"9","key":"10.1016\/j.anpede.2025.503836_bib0055","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.3390\/nu13092907","article-title":"The impact of highly effective CFTR modulators on growth and nutrition status","volume":"13","author":"Bass","year":"2021","journal-title":"Nutrients."},{"issue":"6","key":"10.1016\/j.anpede.2025.503836_bib0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0198457","article-title":"Altered intestinal microbiota composition, antibiotic therapy and intestinal inflammation in children and adolescents with cystic fibrosis","volume":"13","author":"De Freitas","year":"2018","journal-title":"PLoS One."},{"issue":"6","key":"10.1016\/j.anpede.2025.503836_bib0065","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jcf.2016.10.009","article-title":"Biomarkers for cystic fibrosis drug development","volume":"15","author":"Muhlebach","year":"2016","journal-title":"J Cyst Fibros."},{"issue":"1","key":"10.1016\/j.anpede.2025.503836_bib0070","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir Med."},{"key":"10.1016\/j.anpede.2025.503836_bib0075","first-page":"30081","article-title":"CFTR Modulator therapies - effect on life expectancy in people with cystic fibrosis","volume":"20","author":"Balfour-Lynn","year":"2020","journal-title":"Paediatr Respir Rev"},{"issue":"3","key":"10.1016\/j.anpede.2025.503836_bib0080","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11894-021-00806-5","article-title":"Luminal gastrointestinal manifestations of cystic fibrosis","volume":"23","author":"J Burton","year":"2021","journal-title":"Curr. Gastroenterol. Rep."},{"key":"10.1016\/j.anpede.2025.503836_bib0085","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.jcf.2014.02.007","article-title":"Improvement of digestive health and reduction in proteobacterial populations in the gut microbiota of cystic fibrosis patients using a Lactobacillus reuteri probiotic preparation: a double blind prospective study","volume":"13","author":"Del Campo","year":"2014","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.anpede.2025.503836_bib0090","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/MPG.0000000000003046","article-title":"The use of fecal calprotectin testing in paediatric disorders: a position paper of the European Society for Paediatric Gastroenterology and Nutrition Gastroenterology Committee","volume":"72","author":"Koninckx","year":"2021","journal-title":"J Pediatr Gastroenterol Nutr."},{"issue":"1","key":"10.1016\/j.anpede.2025.503836_bib0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5223\/pghn.2022.25.1.1","article-title":"Fecal calprotectin and phenotype severity in patients with cystic fibrosis: a systematic review and meta-analysis","volume":"25","author":"Talebi","year":"2022","journal-title":"Pediatr Gastroenterol Hepatol Nutr."},{"issue":"1","key":"10.1016\/j.anpede.2025.503836_bib0100","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-36364-6","article-title":"Impact of CFTR modulation with ivacaftor on gut microbiota and intestinal inflammation","volume":"8","author":"Ooi","year":"2018","journal-title":"Sci Rep."},{"issue":"6","key":"10.1016\/j.anpede.2025.503836_bib0105","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.jcf.2022.03.012","article-title":"Effects of ivacaftor on systemic inflammation and the plasma proteome in people with CF and G551D","volume":"21","author":"Hoppe","year":"2022","journal-title":"J Cyst Fibros."},{"issue":"6","key":"10.1016\/j.anpede.2025.503836_bib0110","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/MPG.0000000000002864","article-title":"Reduced intestinal inflammation with lumacaftor\/ivacaftor in adolescents with cystic fibrosis","volume":"71","author":"T\u00e9tard","year":"2020","journal-title":"J Pediatr Gastroenterol Nutr."},{"issue":"10","key":"10.1016\/j.anpede.2025.503836_bib0115","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1164\/rccm.202204-0734OC","article-title":"A phase 3, Open-Label Study of Lumacaftor\/Ivacaftor in Children 1 to Less Than 2 Years of Age with Cystic Fibrosis Homozygous for F508del-CFTR","volume":"206","author":"Rayment","year":"2022","journal-title":"Am J Respir Crit Care Med."},{"issue":"5","key":"10.1016\/j.anpede.2025.503836_bib0120","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01175-23","article-title":"Tezacaftor\/Ivacaftor therapy has negligible effects on the cystic fibrosis gut microbiome","volume":"11","author":"Marsh","year":"2023","journal-title":"Microbiol Spectr."},{"issue":"2","key":"10.1016\/j.anpede.2025.503836_bib0125","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jcf.2022.10.003","article-title":"Elexacaftor\/tezacaftor\/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GI","volume":"22","author":"Schwarzenberg","year":"2023","journal-title":"J Cyst Fibros."},{"issue":"2","key":"10.1016\/j.anpede.2025.503836_bib0130","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.01935-23","article-title":"Longitudinal profiling of the intestinal microbiome in children with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor","volume":"15","author":"Reasoner","year":"2024","journal-title":"mBio."}],"container-title":["Anales de Pediatr\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2341287925001243?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2341287925001243?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T15:35:23Z","timestamp":1747755323000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2341287925001243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2341287925001243"],"URL":"https:\/\/doi.org\/10.1016\/j.anpede.2025.503836","relation":{},"ISSN":["2341-2879"],"issn-type":[{"value":"2341-2879","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improvement of intestinal inflammation after treatment with CFTR modulators in cystic fibrosis patients","name":"articletitle","label":"Article Title"},{"value":"Anales de Pediatr\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anpede.2025.503836","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.anpedi.2025.503836","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Asociaci\u00f3n Espa\u00f1ola de Pediatr\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"503836"}}